{"title":"Gestational diabetes mellitus is associated with a low serum level of mitochondrial-derived peptide-MOTS-C","authors":"Serdar Özer, Filiz Alkan Baylan, Abdullah Tok","doi":"10.1515/tjb-2022-0097","DOIUrl":null,"url":null,"abstract":"Abstract Objectives Although MOTS-C has been reported to have a role in diabetes mellitus, no human studies have evaluated the serum level of MOTS-C in GDM. It was aimed to investigate serum levels of MOTS-C in patients with gestational diabetes mellitus (GDM). Methods Comparisons were made of 44 pregnant patients diagnosed with GDM and a control group of 44 healthy pregnant women in respect of serum MOTS-C, insulin, and glucose levels, and serum lipid profile. Results A significantly higher level of fasting serum glucose and significantly lower serum levels of MOTS-C and high density lipoprotein were determined in the GDM group compared to the control group (p<0.05 for all). A cut-off value of 173.5 ng/mL for serum MOTS-C level had sensitivity of 81.8 % and specificity of 61.4 % for GDM diagnosis (p<0.001). A significant correlation was determined between the serum MOTS-C and serum glucose levels (r=−0.239, p=0.025). Conclusions For the first time in literature, the results of this study showed that patients with GDM had a decreased serum level of MOTS-C and that increasing serum MOTS-C levels were associated with a decrease in serum glucose levels, thereby supporting the view that mitochondrial dysfunction plays a role in GDM pathogenesis. Therefore, MOTS-C could be a promising diagnostic biomarker for GDM cases.","PeriodicalId":92463,"journal":{"name":"Turk biyokimya dergisi = Turkish journal of biochemistry","volume":"25 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turk biyokimya dergisi = Turkish journal of biochemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/tjb-2022-0097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract Objectives Although MOTS-C has been reported to have a role in diabetes mellitus, no human studies have evaluated the serum level of MOTS-C in GDM. It was aimed to investigate serum levels of MOTS-C in patients with gestational diabetes mellitus (GDM). Methods Comparisons were made of 44 pregnant patients diagnosed with GDM and a control group of 44 healthy pregnant women in respect of serum MOTS-C, insulin, and glucose levels, and serum lipid profile. Results A significantly higher level of fasting serum glucose and significantly lower serum levels of MOTS-C and high density lipoprotein were determined in the GDM group compared to the control group (p<0.05 for all). A cut-off value of 173.5 ng/mL for serum MOTS-C level had sensitivity of 81.8 % and specificity of 61.4 % for GDM diagnosis (p<0.001). A significant correlation was determined between the serum MOTS-C and serum glucose levels (r=−0.239, p=0.025). Conclusions For the first time in literature, the results of this study showed that patients with GDM had a decreased serum level of MOTS-C and that increasing serum MOTS-C levels were associated with a decrease in serum glucose levels, thereby supporting the view that mitochondrial dysfunction plays a role in GDM pathogenesis. Therefore, MOTS-C could be a promising diagnostic biomarker for GDM cases.